COUCH Health Finds Reasons Behind Underrepresentation of Ethnic Minorities in US & UK Trials
COUCH Health has released new research exploring reasons behind the underrepresentation of ethnic minorities in US & UK clinical trials. Also addressed are how clinical trial communication strategies can be improved to better engage people from diverse backgrounds and ethnicities.
COUCH Health’s research findings suggest that participation from ethnic minorities continues to be low, even while COVID-19 has raised awareness of the importance of clinical trials among potential recruits and as the pharmaceutical industry has begun to tackle its diversity and inclusion problem. Many participants expressed their mistrust in so-called Big-Pharma, concern about being exploited and dehumanized, suspicion over the financial motives of the pharmaceutical industry, and disparities in the quality of care they might receive.
This research follows on from a study based in the United Kingdom, which found a similar reluctance from ethnic minorities to participate in clinical trials in the country. Both studies make several recommendations for better engaging potential recruits, including reaching out to community leaders, building tailored communication strategies per ethnic group, and providing complete information and transparency at every stage of the process.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
